Abstract 277P
Background
To characterize ductal adenocarcinoma of the prostate by comparing VASH1 expression levels in ductal and acinar adenocarcinoma of the prostate.
Methods
125 patients who underwent radical prostatectomy or transrectal resection over the past 5 years, 14 patients diagnosed with ductal adenocarcinoma and 20 patients with acinar adenocarcinoma with Gleason scores of 4+4 were included in the study. VASH1 density was taken as the number of activated endothelial cells (number of vessels per mm2), microvessel density (MVD) was determined through CD34 expression, all results were obtained by immunohistochemistry. The main method for evaluating the results was to determine the presence of a relationship between MVD and VASH1 density in ductal and acinar adenocarcinoma, the secondary method for evaluating the results was the oncological outcomes of these forms of cancer.
Results
9 patients (64.3%) with ductal adenocarcinoma were diagnosed with advanced clinical stage and 5 patients (35.7%) died of cancer during a median follow-up period of 56.0 months. VASH1 density (mean ± SD) in ductal and acinar adenocarcinoma was 45.1 ± 18.5 vs. 16.1 ± 21.0 (p < 0.001), respectively, while MVD (mean ± SD) in ductal and acinar adenocarcinoma was 65.3 ± 21.9 versus 80.8 ± 60.7. (p = 0.666), respectively. The five-year survival rate for high and low VASH1 expression was 70.0% and 100.0% (p = 0.006), respectively. High expression of VASH1 and diagnosis of ductal adenocarcinoma were important predictors of survival.
Conclusions
Ductal adenocarcinoma has more aggressive growth and higher expression of VASH1 than acinar adenocarcinoma, with MVD rates being equivalent in both forms of prostate cancer. The obtained results suggest that the level of VASH1 expression may be a new biomarker for the aggressive course of ductal adenocarcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Cancer Research Center of Uzbekistan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract